1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Biermann JS, Adkins DR, Agulnik M,
Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT,
Frassica DA, et al: Bone cancer. J Natl Compr Canc Netw.
11:688–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Xia L, Zheng R, Xu Y, Xu X, Zhang S, Zeng
H, Lin L and Chen W: Incidence and mortality of primary bone
cancers in China, 2014. Chin J Cancer Res. 31:135–143. 2019.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Sasaki R, Osaki M and Okada F:
MicroRNA-based diagnosis and treatment of metastatic human
osteosarcoma. Cancers (Basel). 11:5532019. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
9
|
Jin C, Rajabi H and Kufe D: miR-1226
targets expression of the mucin 1 oncoprotein and induces cell
death. Int J Oncol. 37:61–69. 2010.PubMed/NCBI
|
10
|
Zhou Q, Zeng H, Ye P, Shi Y, Guo J and
Long X: Differential microRNA profiles between
fulvestrant-resistant and tamoxifen-resistant human breast cancer
cells. Anticancer Drugs. 29:539–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chen X, Tan W, Li W, Li W, Zhu S, Zhong J,
Shang C and Chen Y: miR-1226-3p promotes sorafenib sensitivity of
hepatocellular carcinoma via downregulation of DUSP4 expression. J
Cancer. 10:2745–2753. 2019. View Article : Google Scholar : PubMed/NCBI
|
12
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer; Heidelberg: 2017, View Article : Google Scholar
|
13
|
Wickham H, François R, Henry L and Müller
K: dplyr: A grammar of data manipulation. R package version 0.7.6,
2018. https://CRAN.R-project.org/package=dplyrDecember
16–2019
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Song B, Zhang C, Li G, Jin G and Liu C:
miR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Lee S, Paulson KG, Murchison EP, Afanasiev
OK, Alkan C, Leonard JH, Byrd DR, Hannon GJ and Nghiem P:
Identification and validation of a novel mature microRNA encoded by
the merkel cell polyomavirus in human merkel cell carcinomas. J
Clin Virol. 52:272–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Zhao H, Zheng Y, You J, Xiong J, Ying S,
Xie L, Song X, Yao Y, Jin Z and Zhang C: Tumor suppressor role of
miR-876-5p in gastric cancer. Oncol Lett. 20:1281–1287. 2020.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Hacker H, Tseng PH and Karin M: Expanding
TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev
Immunol. 11:457–468. 2011. View
Article : Google Scholar : PubMed/NCBI
|
23
|
Tseng PH, Matsuzawa A, Zhang W, Mino T,
Vignali DA and Karin M: Different modes of ubiquitination of the
adaptor TRAF3 selectively activate the expression of type I
interferons and proinflammatory cytokines. Nat Immunol. 11:70–75.
2010. View
Article : Google Scholar : PubMed/NCBI
|
24
|
Perkins DJ, Polumuri SK, Pennini ME, Lai
W, Xie P and Vogel SN: Reprogramming of murine macrophages through
TLR2 confers viral resistance via TRAF3-mediated, enhanced
interferon production. PLoS Pathog. 9:e10034792013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Rehei AL, Zhang L, Fu YX, Mu WB, Yang DS,
Liu Y, Zhou SJ and Younusi A: MicroRNA-214 functions as an oncogene
in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol
Sci. 22:5156–5164. 2018.PubMed/NCBI
|
26
|
Lalani AI, Luo C, Han Y and Xie P: TRAF3:
A novel tumor suppressor gene in macrophages. Macrophage (Houst).
2:e10092015.PubMed/NCBI
|
27
|
Whillock AL, Mambetsariev N, Lin WW, Stunz
LL and Bishop GA: TRAF3 regulates the oncogenic proteins Pim2 and
c-Myc to restrain survival in normal and malignant B cells. Sci
Rep. 9:128842019. View Article : Google Scholar : PubMed/NCBI
|
28
|
Kotsaris G, Kerselidou D, Koutsoubaris D,
Constantinou E, Malamas G, Garyfallos DA and Ηatzivassiliou EG:
TRAF3 can interact with GMEB1 and modulate its anti-apoptotic
function. J Biol Res (Thessalon). 27:72020. View Article : Google Scholar : PubMed/NCBI
|
29
|
Marcellus RC, Teodoro JG, Charbonneau R,
Shore GC and Branton PE: Expression of p53 in Saos-2 osteosarcoma
cells induces apoptosis which can be inhibited by Bcl-2 or the
adenovirus E1B-55 kDa protein. Cell Growth Differ. 7:1643–1650.
1996.PubMed/NCBI
|
30
|
Li W, Fan J, Hochhauser D, Banerjee D,
Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl GM and Bertino JR:
Lack of functional retinoblastoma protein mediates increased
resistance to antimetabolites in human sarcoma cell lines. Proc
Natl Acad Sci USA. 92:10436–10440. 1995. View Article : Google Scholar : PubMed/NCBI
|
31
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|